Article Text
Letter
Adalimumab: a new modality for Behçet’s disease?
Statistics from Altmetric.com
Footnotes
-
Published Online 23 November 2006
-
Competing interests: PMvH has cooperated in a European study on patients with uveitis treated with infliximab that was sponsored by Centocor. JAMvL and PMvH were in part sponsored to visit the 12th international Behçet’s congress in Lisbon by Abbott BV where JAMvL presented these data to the international investigators on Behçet’s disease.